Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease

Respiration

Volumn 86, Issue 4, 2013, Pages 280-287

  Hoshino, Makoto ^a   Ohtawa, Junichi ^a  

^a International University of Health and Welfare   (Japan)

Author keywords

Airway remodeling; Chronic obstructive pulmonary disease; Computed tomography; Salmeterol; Salmeterol fluticasone combination; Tiotropium

Indexed keywords

ADAIR; FLUTICASONE PROPIONATE; HANDIHALER; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; BUDESONIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO;

AGED; AIRWAY REMODELING; AIRWAY WALL THICKNESS; ARTICLE; BODY SURFACE; BRONCHUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; RESPIRATORY TRACT PARAMETERS; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TOTAL LUNG CAPACITY; ADULT; AIRWAY; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG EFFICACY; DRY POWDER INHALER; LUNG VOLUME; PREDICTIVE VALUE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 84888071168     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000351116     Document Type: Article

References (46)

1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2010. http://www.goldcopd.org/.
2. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K: Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.
3. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
4. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
5. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
6. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
7. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ: Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-222.
8. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJ: Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010; 104: 995-1004.
9. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2007. http://www.goldcopd.com.
10. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
11. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
12. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
13. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
14. Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M: A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20: 556-561.
15. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ: Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598.
16. Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Paré PD, Hogg JC, Mishima M: Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
17. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M: Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 1309-1315.
18. Thurlbeck WM, Müller NL: Emphysema: definition, imaging, and quantification. Am J Roentgenol 1994; 163: 1017-1125.
19. Foster WL Jr, Pratt PC, Roggli VL, Godwin JD, Halvorsen RA Jr, Putman CE: Centrilobular emphysema: CT-pathologic correlation. Radiology 1986; 159: 27-232.
20. Bergin C, Müller N, Nichols DM, Lillington G, Hogg JC, Mullen B, Grymaloski MR, Osborne S, Paré PD: The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986; 133: 541-546.
21. Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM, Hogg JC, Paré PD: The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005; 171: 142-146.
22. Orlandi I, Moroni C, Camiciottoli G, Bartolucci M, Pistolesi M, Villari N, Mascalchi M: Chronic obstructive pulmonary disease: thinsection CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 604-610.
23. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Nakajima Y: Airway dimensions on inspiratory and expiratory multisection CT in chronic obstructive pulmonary disease: correlation with airflow limitation. Radiology 2008; 248: 1042-1049.
24. Okazawa M, Müller N, McNamara AE, Child S, Verburgt L, Paré PD: Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996; 154: 1557-1562.
25. Matsuoka S, Kurihara Y, Nakajima Y, Niimi H, Ashida H, Kaneoya K: Serial change in airway lumen and wall thickness at thin-section CT in asymptomatic subjects. Radiology 2005; 234: 595-603.
26. Hoshino M, Matsuoka S, Handa H, Miyazawa T, Yagihashi K: Correlation between airflow limitation and airway dimensions assessed by multidetector CT in asthma. Respir Med 2010; 104: 794-800.
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
28. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
29. Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y: Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. Respirology 2009; 14: 239-244.
30. Ronchi MC, Piragino C, Rosi E, Amendola M, Duranti R, Scano G: Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax 1996; 51: 1000-1004.
31. Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, Andersson B: Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 1995; 50: 360-365.
32. St?nescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, Maestrelli P: Airways obstruction, chronic expectoration, and rapid decline of FEV 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-271.
33. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a doubleblind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
34. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK: Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
35. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q: Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943.
36. Roth M, Johnson PR, Rüdiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL: Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
37. Hoshino M, Ohtwa J: Effects of budesonide/formoterol combination versus budesonide on airway dimensions in asthma. Respirology 2012; 17: 639-646.
38. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M: Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998; 274:L970-L979.
39. Emala CW, Clancy J, Hirshman CA: Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle. Am J Physiol 1997; 272:L745-L751.
40. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Halayko AJ, Meurs H, Zaagsma J: Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007; 30: 653-661.
41. Gosens R, Bos IS, Zaagsma J, Meurs H: Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005; 171: 1096-1102.
42. Grydeland TB, Dirksen A, Coxson HO, Eagan TM, Thorsen E, Pillai SG, Sharma S, Eide GE, Gulsvik A, Bakke PS: Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med 2010; 181: 353-359.
43. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
44. Hasegawa M, Makita H, Nasuhara Y, Odajima N, Nagai K, Ito Y, Betsuyaku T, Nishimura M: Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 2009; 64: 332-338.
45. Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD: Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Resp Med 2012; 106: 382-389.
46. Aysola RS, Hoffman EA, Gierada D, Wenzel S, Cook-Granroth J, Tarsi J, Zheng J, Schechtman KB, Ramkumar TP, Cochran R, Xueping E, Christie C, Newell J, Fain S, Altes TA, Castro M: Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134: 1183-1191.